GTBP GT Biopharma Inc

1,606

$0.2251

$0.0031

(1.40%)

Today

Market Cap	$9.32M
Volume (M)	86,632.00
52-Wk High	$1.74
52-Wk Low	$0.1797

ST Data

Watchers

New Watcher Rank

Fundamentals

GT Biopharma: ISS, Glass Lewis recommend shareholders vote for proposed itemsThe Fly • 3 days ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Share to Feed

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote FOR All Proposed Items at the Upcoming Special Meeting of StockholdersGlobe Newswire • 3 days ago

The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT...

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ LeukemiaGlobe Newswire • 5 days ago

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingGlobe Newswire • about 1 month ago

BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...

GT Biopharma GAAP EPS of -$0.06SeekingAlpha.com: All News • about 1 month ago

GT Biopharma GAAP EPS of -$0.06...

GT Biopharma Reports Third Quarter 2023 Financial ResultsGlobe Newswire • about 1 month ago

IND submission for GTB-3650, 2nd generation nanobody TriKE for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia...

HC Wainwright Weighs in on GT Biopharma, Inc.'s Q3 2023 Earnings (NASDAQ:GTBP)Zolmax • 4 months ago

GT Biopharma, Inc. (NASDAQ:GTBP Free Report) Research analysts at HC Wainwright increased their Q3 2023 earnings per share estimates for shares of GT Biopharma in a research report issued to clients and investors on Tuesday, August 8th. HC Wainwright analyst R. Burns now expects that the company ...

GT Biopharma (NASDAQ:GTBP) Earns "Buy" Rating from HC WainwrightZolmax • 4 months ago

HC Wainwright reissued their buy rating on shares of GT Biopharma (NASDAQ:GTBP Free Report) in a research note published on Tuesday , Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for GT Biopharmas Q3 2023 earnings...

Equities Analysts Offer Predictions for GT Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:GTBP)Zolmax • 4 months ago

GT Biopharma, Inc. (NASDAQ:GTBP Free Report) Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of GT Biopharma in a research note issued to investors on Tuesday, August 8th. HC Wainwright analyst R. Burns expects that the company will post earnings of...

H.C. Wainwright Remains a Buy on GT Biopharma (GTBP)TipRanks Financial Blog • 4 months ago

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on GT Biopharma (GTBP Research Report) today and set a price target of $5.00. The co... H.C. Wainwright analyst Robert Burns reiterated a Buy rating on GT Biopharma (GTBP Research Repo...